Amgen Victory In TKT Litigation Eases Pressure To Seek NESP Reimbursement

Amgen's victory in the erythropoietin patent infringement case against Transkaryotic Therapies takes some pressure off the company to seek reimbursement for its novel erythropoiesis stimulating protein Aranesp (darbepoetin alfa).